The company is currently based in The Woodlands and is moving its headquarters to Conroe. VGXI first announced it was producing a vaccine for the coronavirus in early January with a clinical study beginning in late summer. According to a VGXI news release, the facility will also support a wide range or projects from early clinical stages through commercial supply.
The site includes over 21 acres in the initial acquisition with an option to purchase an additional 21 acres for future expansion, according to a news release from VGXI.
The design development phase of the project is underway with groundbreaking planned in the third quarter of this year and substantial completion targeted by the third quarter of 2021. The first phase of the facility is expected to be operational by January 2022.
“Demand for high quality and reliable plasmid manufacturing services has increased dramatically as DNA immunotherapy and gene therapies demonstrate success in clinical studies,” VGXI CEO Young Park said in the news release. “The established site for our new facility and multi-phase expansion strategy enables VGXI to continue to grow and support the success of our clients’ products as these industries mature.”
